<DOC>
	<DOCNO>NCT00591201</DOCNO>
	<brief_summary>Tumor necrosis factor ( TNF ) alpha pro-inflammatory cytokine playing significant role pathogenesis spondyloarthropathies ( SpA ) . Infliximab TNF alpha block monoclonal antibody efficacious safe treatment adult-onset SpA . In study try demonstrate infliximab administer 5mg/kg patient juvenile onset SpA period 12 week efficacy placebo well tolerate . At end phase , patient go 52-week open extension demonstrate sustain efficacy , safety , tolerability infliximab We include 34 patient juvenile onset SpA unresponsive standard treatment . Efficacy assess count number actively inflamed joint number parameter .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Study Infliximab Juvenile Spondyloarthropathies</brief_title>
	<detailed_description>Background Tumor necrosis factor ( TNF ) alpha pro-inflammatory cytokine playing significant role pathogenesis spondyloarthropathies ( SpA ) . Infliximab TNF alpha block monoclonal antibody efficacious safe treatment adult-onset SpA . Hypothesis Infliximab reduce number joint active arthritis improve additional parameter disease activity function significantly placebo 12 week . Infliximab demonstrate sustain efficacy administration safe well tolerate 52 week . Objectives To demonstrate superior clinical efficacy infliximab administer 5mg/kg compare placebo , juvenile onset SpA period 12 week . To demonstrate sustained efficacy , safety , tolerability infliximab 5 mg/kg 52 week . Study Design This two-phase study . First phase : 12-week , randomize , double-blind , placebo-controlled period evaluate efficacy , safety , tolerability infliximab 5 mg/kg . Thirty-four patient allocate randomized infliximab 5 mg/kg placebo . Randomization : restrict block four stratification two diagnostic category ( undifferentiated SpA ankylose spondylitis ) . Efficacy analysis : change primary efficacy measure secondary measure week 2 , 6 , 12 , visit discontinuation compare week 0 compare change placebo group . Patients complete 1st phase discontinue due lack efficacy week 6 continue 2nd phase complete total 52 week . The 2nd open-phase demonstrate sustain efficacy , safety , tolerability infliximab along 52 week ( week 12 , 18 , 24 , 30 , 36 , 42 48 ) . Efficacy analysis focus change primary efficacy measurement secondary measure schedule visits- discontinuation visit compare week 0 . Safety Evaluation Safety evaluation include search clinical serious non-serious adverse event ; blood cytology , hepatic function test , blood chemistry , urinanalysis , antinuclear antibody immunofluorescence , anti-DNA antibody , rheumatoid factor , chest X-rays . Statistical Analysis The primary analysis follow `` intention treat '' model . The data patient prematurely discontinue study- since V2.0- include primary analysis . The comparison infliximab placebo sequential . Double-blind phase : step-down analysis ; change baseline compute time-weighted average response across week 2 , 4 , 6 -and discontinuation visit . 95 % confidence interval evaluate magnitude difference infliximab placebo use . Open phase : mean change baseline time weighted average response whole length study . Statistical test : parametric non parametric evaluate inter intragroupal difference ; ANCOVA , Mann Whitney , Wilcoxon , student x2 . Sample size : 17 patient per group , plus 2 patient per group loss , suppose improvement study group 60 % 90 % , confidence level 95 % 99 % ( two tail test ) power 80 % 90 % , improvement control group 10 % . The basis calculation indirect data juvenile SpA ; yet , data adult treat infliximab child teenager treat sulfasalazine compare placebo exist . Budget The project protocol result initiative investigator intellectual proprietary . Schering Plough , owner patent Infliximab ( Remicade ; Schering Plough ) , accept finance project .</detailed_description>
	<mesh_term>Spondylarthropathies</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Ages le tha 16 year symptoms onset less 18 year entry SpA diagnosis ( ESSG criterion ) Active arthritis least 2 peripheral joint Pressure tenderness least 3 peripheral entheses Pain intensity 40 mm analogue visual scale ( VAS ) Lack response NSAID , sulfasalazine methotrexate Serum HCGbeta level congruent pregnancy Use doublebarrier contraceptive method History BCG vaccination Capacity understand study follow protocol instruction Written sign consent letter . Exclusion criterion : Pregnancy lactation Mental disability Functional class IV Psoriasis , reactive arthritis inflammatory bowel disease Infectious , neoplastic , metabolic , hepatic , hematological , vascular , cardiopulmonary renal active disease Opportunistic infectious Active tuberculosis Significant laboratory test abnormalities Current prednisone dose 10 mg/day ; Intraarticular/muscular/venous glucocorticoid Previous use Infliximab etanercept , pentoxyphylline , thalidomide , antiCD4 antibody Allergy hypersensitivity infliximab Significant drug change within one month screen Use recreational drugs/illicit substance .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Spondylarthritis</keyword>
	<keyword>TNF</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Ankylosing spondylitis</keyword>
	<keyword>Juvenile SpA</keyword>
	<keyword>Juvenile arthritis</keyword>
</DOC>